Adaptimmune Therapeutics plc (ADAP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 03:08PM EDT. Market open.
| Previous Close | 1.1500 |
| Open | 1.1500 |
| Bid | 1.0800 x 600 |
| Ask | 1.1100 x 200 |
| Day's Range | 1.0600 - 1.1500 |
| 52 Week Range | 0.4200 - 2.0500 |
| Volume | |
| Avg. Volume | 1,511,457 |
| Market Cap | 279.84M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
- Simply Wall St.
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...
- GuruFocus.com
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
Key Financial Highlights and Business Updates
© 2024 Yahoo. All rights reserved.